Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™
1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Fibrosis Patients 2. Iclaprim Demonstrates Potent In Vitro Suppression of Exotoxins in MRSA Isolates NEW YORK, Oct. 06, 2017 (GLOBE …